First Approved CRISPR Therapy: Casgevy’s 2026 Numbers
Three years after the first approved CRISPR therapy reached the market, there are numbers instead of predictions. Only 64 patients received Casgevy in all of 2025 — even as 90% of eligible U.S. patients gained reimbursed access. The gap between approval and arrival is where the real work sits.









